GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression.

Key Points

• This research aims to explore how GLP-2 impacts osteoblasts to combat postmenopausal osteoporosis through molecular pathways.
• Activated PI3K/AKT/FOXO1 pathway in osteoblasts using GLP-2 treatment
• Monitored FGF23 expression levels in response to GLP-2
• Analyzed the effect on osteoporosis in a postmenopausal model
• GLP-2 effectively activates the PI3K/AKT/FOXO1 pathway in osteoblasts
• Significant downregulation of FGF23 expression observed
• Improved indicators of osteoporosis noted in treated models